Showing results (91-100 of 99) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 99 results.
Blood|October 18, 2012
Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic responseAmir T Fathi, Hossein Sadrzadeh, Darrell R Borger, et al.
Cancer|November 14, 2018
Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemiaAndrew M Brunner, Donna S Neuberg, Seth A Wander, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2023
Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid LeukemiaAmir T Fathi, Haesook T Kim, Robert J Soiffer, et al.
Leukemia & Lymphoma|March 12, 2025
Ixazomib in addition to chemotherapy for the treatment of acute myeloid leukemia in older adultsPhilip C Amrein, Frederic I Preffer, Geoffrey Fell, et al.
Haematologica|December 31, 2016
Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemiaAmir T Fathi, Seth A Wander, Traci M Blonquist, et al.
Cancer|September 30, 2017
Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutationAmir T Fathi, Traci M Blonquist, Daniela Hernandez, et al.
Cancer|December 21, 2019
A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemiaRupa Narayan, Traci M Blonquist, Ashkan Emadi, et al.
Genes & Development|March 5, 2014
D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in miceEsra A Akbay, Javid Moslehi, Camilla L Christensen, et al.
The Lancet. Haematology|December 16, 2019
Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trialAndrew M Brunner, Traci M Blonquist, Daniel J DeAngelo, et al.
Pageof 10